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Regression and progression of microalbuminuria in 
adolescents with childhood onset diabetes mellitus
Original article
Purpose: Although microalbuminuria is considered as an early marker of 
nephropathy in diabetic adults, available information in diabetic adolescents 
is limited. The aim of this study was to investigate prevalence and frequency of 
regression of microalbuminuria in type 1 (T1DM) and type 2 diabetes mellitus 
(T2DM) patients with childhood onset.
Methods: One hundred and nine adolescents (median, 18.9 years; interquartile 
range (IQR), 16.5–21.0 years) with T1DM and 18 T2DM adolescents (median, 17.9 
years; IQR, 16.8–18.4 years) with repeated measurements of microalbuminuria (first 
morning urine microalbumin/creatinine ratios) were included. The median duration 
of diabetes was 10.1 (7.8–14.0) years and 5.0 (3.5–5.6) years, respectively, and 
follow-up period ranged 0.5–7.0 years. Growth parameters, estimated glomerular 
filtration rate, glycosylated hemoglobin (HbA1c) and lipid profiles were obtained 
after reviewing medical record in each subject.
Results: The prevalence of microalbuminuria at baseline and evaluation were 21.1% 
and 17.4% in T1DM, and 44.4% and 38.9% in T2DM. Regression of microalbuminuria 
was observed in 13 T1DM patients (56.5%) and 3 T2DM patients (37.5%), and 
progression rate was 10.5% and 20% in T1DM and T2DM respectively. In regression 
T1DM group, HbA1c at baseline and follow-up was lower, and C-peptide at 
baseline was higher compared to persistent or progression groups. In T2DM, higher 
triglyceride was observed in persistent group.
Conclusion: Considerable regression of microalbuminuria more than progression in 
diabetes adolescents indicates elevated urinary microalbumin excretion in a single 
test does not imply irreversible diabetic nephropathy. Careful monitoring and 
adequate intervention should be emphasized in adolescents with microalbuminuria 
to prevent rapid progression toward diabetic nephropathy.
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Introduction
Microalbuminuria is known as an early marker of nephropathy and cardiovascular diseases 
in adults with diabetes1-4) and hypertension5). In patients with childhood onset diabetes, the 
cumulative prevalence of microalbuminuria is about 25%–30% after 10 years of diabetes, 
and 40%–60% after 20 years of diabetes6,7). International Society for Pediatric and Adolescent 
Diabetes, The American Diabetes Association and National Kidney Foundation recommend 
annual screening for microalbuminuria in children from 9 years of age with 5 years of insulin 
dependent diabetes mellitus (IDDM) duration, from 11 years of age with 2 years of IDDM 
duration, and adolescent with 2 years or more of IDDM duration8,9). 
Regression of microalbuminuria was reported in type 1 diabetes adults that occurred in 58% 
of the patients with a 6-year cumulative incidence of microalbuminuria, and modifiable factors 
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were low glycosylated hemoglobin (HbA1c) levels, low blood 
pressure and low levels of lipid concentration10). Regression of 
microalbuminuria over six years was also occurred in 31% of 
adults with type 1 diabetes in Denmark11). In a pediatric study 
conducting type 1 diabetic children, cumulative incidence of 
microalbuminuria was 26% after 10 years of follow-up, of them 
39% had regression to normoalbuminuria without recurrence6).
It was also reported that 72% of type 1 diabetic children had 
regression to normoalbuminuria using repeated random spot 
urine tests in a single center study12). Therefore there is a focus 
on early detection and prevention of complications through 
routine screening and careful monitoring as well as adequate 
control of  blood glucose and blood pressure in diabetic 
children12). 
In this study, we investigated prevalence and frequency of 
regression of microalbuminuria in adolescents with childhood 
onset type 1 (T1DM) and type 2 diabetes mellitus (T2DM).  
Materials and methods
1. Subjects
A total of 127 patients (83 males and 44 females, 8–28 years) 
with childhood onset T1DM or T2DM, who visited department 
of pediatrics, Konkuk University Medical Center and Childhood 
Diabetes Clinic of Severance Children’s Hospital were included 
from July 2007 to July 2014. One hundred and nine patients 
were T1DM and 18 patients were T2DM. Diabetic patients with 
macroalbuminuria or overt proteinuria, hematuria, menstrual 
bleeding, infections, fever, and other renal diseases were 
excluded. Confirmed cases of diabetic nephropathy treated with 
medication were also excluded in this study. 
2. Anthropometric and laboratory data measurements
Height and body weight were measured with a stadiometer 
and a calibrated digital electric scale, and body mass index 
(BMI) was calculated in each subject. The z-scores of height, 
weight, and BMI were obtained by Lambda-Mu-Sigma (LMS) 
method3,13). Serum creatinine, HbA1c, C-peptide and lipid 
profiles were obtained. Estimated glomerular filtration rate 
(eGFR) was calculated using the Schwartz formula: eGFR (mL/
min/1.73 m2)=κ×height (cm)/serum creatinine (mg/dL)14). The 
value of κ was determined to be 0.55 for children aged between 
2 and 13 years and adolescent girls, and 0.70 for adolescent boys. 
First morning urine sample was obtained in all patients, 
with an average of 2.7 urine samples per a patient. Three or 
more urine samples were collected in 24.4% and 2 samples 
collected in 75.6% of the patients. Baseline was the time of 
initial measurement of microalbuminuria, not meant by the 
time of diagnosis as diabetes. Follow-up was the time of last 
measurement of microalbuminuria. Spot urine microalbumin/
creatinine ratio (mg/g) was measured by the Jaffe method, and 
microalbuminuria is defined as 30–300 mg/g of microalbumin/
creatinine ratio in spot urine15). Persistent microalbuminuria 
was defined as the presence of microalbuminuria at baseline and 
Table 1. Anthropometric and laboratory characteristics of patients with type 1 and type 2 diabetes
Variable
T1DM ( n=109 ) T2DM ( n=18 )
Baseline Follow-up Baseline Follow-up
Anthropometric index
  Age (yr) 17.5a) (15.1–20.5) 18.9 (16.5–21.0) 15.4a) (12.6–17.4) 17.9 (16.8–18.4)
  Sex, male/female 39/70 4/14
  Diabetes duration (yr) 9.5a) (6.5–13.5) 10.1 (7.8–14.0) 0.9a) (0.0–3.0) 5.0 (3.5–5.6)
  Height (cm)    162.0a) (160.0–170.0)     162.9 (160.0–172.0)     158.5a) (153.5–160.5) 160.2 (153.5–163.2)
  Weight (kg) 57.0a) (53.0–64.0)  58.5 (54.0–65.0)     61.0 (54.0–73.7) 63.4 (54.0–75.5)
  BMI (kg/m2)    21.52a) (19.53–23.15)     21.91 (20.03–23.41)       24.74 (21.09–30.88)   24.31 (21.09–29.02)
  Height z-score       0.12a) (–0.44 to 1.19)         0.05 (–0.55 to 0.86)         0.50a) (–0.15 to 0.71)    –0.10 (–1.45 to 0.13)
  Weight z-score         0.31 (–0.17 to 1.00)         0.27 (–0.17 to 1.02)         1.02a) (–0.01 to 2.50)       0.35 (–0.01 to 2.17)
  BMI z-score         0.31 (–0.43 to 0.78)         0.30 (–0.43 to 0.83)          1.29 (–0.02 to 2.49)       0.99 (–0.01 to 2.27)
Biochemical profiles
  Serum creatinine (mg/dL)    0.80 (0.70–0.90)   0.75 (0.69–0.85)     0.80 (0.60–0.90) 0.65 (0.60–0.76)
  eGFR (mL/min/1.73 m2)      125.7 (110.0–134.6)   127.9a) (118.8–136.1)       128.5 (109.9–156.3)   139.6 (129.0–152.1)
  Urine microalbumin/creatinine (mg/g)   9.4 (6.3–26.6) 13.3 (8.6–24.8)    25.3 (11.5–56.0)          17.7 (6.2–42.0)
  Cholesterol (mg/dL)      175.0 (167.0–230.0)     179.0 (163.0–206.0)       194.0 (161.0–231.0)   150.0 (139.0–222.0)
  TG (mg/dL)     79.0 (61.0–101.0)   74.0 (56.0–93.0)     105.0 (85.0–235.0)   92.0 (64.0–262.0)
  HDL-cholesterol (mg/dL)   58.0 (50.0–68.0) 60.0a) (52.0–68.0)     49.5 (43.0–52.0) 53.0 (45.0–59.0)
  HbA1c (%) 8.3 (7.3–9.6) 8.4 (7.4–9.6)     8.8 (6.9–12.2) 7.8 (6.2–11.7)
  C-peptide (ng/mL)        0.02 (0.015–0.039)       0.02 (0.015–0.018)       2.97a) (2.471–3.733)     1.96 (1.432–2.393)
Values are presented as median (interquartile range) or number.
T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus; BMI, body mass index; eGFR, estimated glomerular filtration rate; TG, 
triglyceride; HDL-cholesterol, high density lipoprotein cholesterol; HbA1c, glycosylated hemoglobin; C-peptide, connecting peptide.
a)P<0.005 for baseline vs. follow-up assessments.
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T1DM (n=109) T2DM (n=18) 
Total (n=127) 
Microalbuminuria 
(n=109, 21.1%) 
Normoalbuminuria 
(n=109, 21.1%) 
Microalbuminuria 
(n=8, 44.4%) 
Normoalbuminuria 
(n=10, 55.6%) 
Microalbuminuria 
(n=10, 43.5%) 
Normoalbuminuria 
(n=13, 56.5%) 
Microalbuminuria 
(n=5, 62.5%) 
Normoalbuminuria 
(n=3, 37.5%) 
Microalbuminuria 
(n=9, 10.5%) 
Normoalbuminuria 
(n=77, 89.5%) 
Microalbuminuria 
(n=2, 20%) 
Normoalbuminuria 
(n=8, 80%) 
Persistent Regression Progression Normo 
Albuminuria 
Persistent Regression Progression Normo 
Albuminuria 
Fig. 1. Schematic representation of diabetic patients with persistent, regression, and progression groups to microalbuminuria. T1DM, type 1 diabetes mellitus; T2DM, type 
2 diabetes mellitus.
Table 2. Characteristics of patients with type 1 diabetes according to microalbuminuria status (n=109)
Characteristic
Persistent (n=10) Regression (n=13) Progression (n=9) Normal (n=77)
Baseline Follow-up Baseline Follow-up Baseline Follow-up Baseline Follow-up
Anthropometric index
  Age (yr) 17.8
(14.5–22.5)
19.2
(17.0–23.0)
17.0
(15.0–21.0)
20.0
(17.5–21.5)
19.0
(19.0–24.5)
20.0
(19.5–25.0)
17.5
(15.0–20.5)
18.0
(15.5–21.0)
  Sex, 
    male/female
2/8 4/9 3/6 4/9
  Diabetes 
    duration (yr)
12.0
(7.5–16.0)
12.8
(8.0–16.5)
10.0
(5.0–11.1)
10.5
(7.9–13.0)
11.5
(5.5–15.0)
12.0
(7.5–16.0)
9.5
(6.5–13.5)
10.0
(7.0–14.0)
  Follow-up 
    duration (yr)
0.5 (0.5–1.0)a) 1.0 (0.5–4.0) 0.5 (0.5–1.0)b) 1.0 (0.5–0.5)
  Height z-score 0.10
(–0.15–0.63)
0.11
(–0.15 to 0.53)
–0.15
(–0.41 to 0.28)
–0.22
(–0.55 to 0.26)
0.01
(–0.15 to 0.25)
–0.01
(–0.15 to 0.25)
0.24
(–0.55 to 1.02)
0.15
(–0.55 to 0.86)
  Weight z-score 0.67
(0.32–1.13)
0.68
(0.04–1.02)
0.42
(–0.10–0.71)
0.22
(–0.09 to 1.13)
0.08
(–0.02 to 0.79)
0.08
(–0.02 to 0.79)
0.29
(–0.17 to 0.90)
0.29
(–0.17 to 0.90)
  BMI z-score 0.55
(0.28–0.83)
0.51
(0.12–0.83)
0.39
(–0.12 to 0.76)
0.34
(0.30–0.68)
–0.04
(–0.47 to 0.77)
–0.04
(–0.11 to 0.77)
0.28
(–0.50 to 0.59)
0.25
(–0.50 to 0.59)
Biochemical profiles
  sCr (mg/dL) 0.70
(0.60–0.90)
0.69
(0.65–0.74)
0.80
(0.70–1.00)
0.73
(0.69–0.99)
0.78
(0.60–0.80)
0.75
(0.74–0.81)
0.80
(0.70–0.90)
0.76
(0.69–0.86)
  eGFR (mL/
    min/1.73 m2)
127.7
(110.0–165.0)
129.5
(125.3–156.6)
116.3
(99.4–127.3)
128.3
(119.3–135.4)
117.3
(116.9–148.5)
118.8
(116.5–128.8)
125.7
(110.0–133.6)
127.5
(117.0–136.1)
  Urine 
    microalbumin/
    creatinine
    (mg/g)
63.3
(48.9–171.8)
58.0
(48.0–92.4)
56.4
(34.1–74.0)
9.6
(8.6–15.8)
15.4
(11.4–22.0)
42.1
(30.8–50.2)
7.4
(5.0–10.1)
11.3
(7.8–16.5)
  Cholesterol 
    (mg/dL)
NA NA 175.0
(160.0–214.0)
168.0
(163.0–206.0)
NA NA 181.0
(175.0–187.0)
177.5
(160.0–195.0)
  TG (mg/dL) 70.0
(64.0–135.0)
75.0
(68.0–119.0)
79.5
(67.0–109.0)
77.5
(73–94)
92.0
(81–94)
71.0
(61–89)
76.0
(56–99)
67.0
(53–91)
  HDL-cholesterol 
    (mg/dL)
58.0
(56.0–64.0)
55.0
(53.0–66.0)
58.0
(53.0–67.0)
61.5
(55.0–68.0)
56.0
(45.0–68.0)
60.0
(47.0–75.0)
58.0
(49.0–67.0)
60.0
(52.0–68.0)
  HbA1c (%) 9.8
(8.7–13.8)c)
9.7
(8.9–10.1)d)
8.0
(7.0–8.9)e)
8.0
(7.1–9.4)f )
9.6
(8.5–10.2)
9.5
(7.8–10.1)
8.2
(7.1–9.1)
8.1
(7.2–9.0)
  C-peptide
    (ng/mL)
0.02
(0.015–0.015)
0.02
(0.015–0.018)
0.27
(0.015–0.571)g)
0.02
(0.020–0.050)
0.03
(0.015–0.100)h)
0.04
(0.020–0.092)
0.02
(0.015–0.020)
0.02
(0.015–0.022)
Values are presented as median (interquartile range or range) or number.
T1DM, type 1 diabetes mellitus; BMI, body mass index; sCr, serum creatinine; eGFR, estimated glomerular filtration rate; TG, triglyceride; 
HDL-cholesterol, high density lipoprotein cholesterol; HbA1c, glycosylated hemoglobin; C-peptide, connecting peptide; NA, not available.
a)P<0.001 for regression vs. persistent groups. b)P=0.027 for regression vs. progression groups. c)P=0.009 for persistent, regression, 
progression and normoalbuminuria groups. d)P=0.030 for persistent, regression and progression groups. e)P=0.026 for persistent vs. 
regression groups. f )P=0.042 for persistent vs. regression groups. g)P=0.021 for persistent vs. regression groups. h)P=0.021 for persistent vs. 
progression groups.
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follow up assessment. Regressed or transient microalbuminuria 
was defined as regression of  microalbuminuria to nor-
moalbuminuria during follow-up. Progression of  micro-
albuminuria was defined as normoalbuminuria at baseline 
assessment followed by progression to microalbuminuria6).
Medical record was reviewed retrospectively in each patient.
3. Ethics and confidential data approvals
This study was approved by the Institutional Review Board 
of Konkuk University Medical Center, Seoul, Korea (IRB No. 
KUH1090029).
4. Statistical data analysis
Data are expressed as median (interquartile range [IQR] or 
range), or number and proportion (%). Standard descriptive 
statistics were used to summarize demographic and laboratory 
variables. Changes in variables between baseline and follow-
up were tested using the Wilcoxon signed-rank test. Mann-
Whitney U test was used to compare between two groups, 
and Kruskal Wallis analysis of variance was used for multiple 
comparison. Statistical analyses were performed using IBM 
SPSS Statistics ver. 20.0 (IBM Co., Armonk, NY, USA). All 
reported P-values are two-tailed and P-values less than 0.05 
were considered statistically significant.
Table 3. Characteristics of patients with type 2 diabetes according to microalbuminuria status (n=18)
Characteristic
Persistent (n=5) Regression (n=3) Progression (n=2) Normoalbuminuria (n=8)
Baseline Follow-up Baseline Follow-up Baseline Follow-up Baseline Follow-up
Anthropometric index
  Age (yr) 14.9
(13.3–16.8)
17.9
(17.8–18.1)
14.1
(11.9–26.0)
18.2
(13.8–27.0)
18.9
(15.8–22.0)
19.7
(16.8–22.5)
14.4
(12.3–17.4)
17.0
(15.8–18.4)
  Sex,
    male/female
0/3 0/5 0/2 4/4
  Diabetes 
    duration (yr)
2.6
(0.2–3.0)
5.6
(5.3–6.6)
0.0
(0.0–13.0)
4.1
(1.9–14.0)
2.3
(0.5–4.0)
3.0
(1.0–5.0)
0.7
(0.0–3.0)
4.6
(3.2–5.1)
  Follow-up 
    duration (yr)
4.4 (3.0–5.1) 1.9 (1.0–4.1) 0.8 (0.5–1.0) 2.6 (0.5–5.0)
  Height z-score 0.00
(–0.02 to 0.01)a)
–0.02
(–1.45 to –0.01)
–0.15
(–0.55 to 0.05)
–0.63
(–0.79 to –0.15)
–1.92
(–2.23 to –1.60)
–1.92
(–2.23 to –1.61)
0.65
(0.46–0.98)
0.12
(–0.70 to 0.47)
  Weight z-score 2.33
(1.18–2.50)
1.56
(1.47–2.38)
–0.15
(–2.16 to –0.02)
–0.02
(–3.07–0.04)
0.20
(0.13–0.27)
0.20
(0.13–0.27)
1.74
(0.31–2.68)
0.63
(–0.01 to 2.29)
  BMI z-score 2.10
(1.28–2.85)
2.27
(1.57–2.35)
–0.26
(–2.39 to –0.02)
–0.02
(–2.97 to 0.49)
1.16
(1.00–1.31)
1.13
(0.94–1.31)
1.83
(–0.07 to 2.57)
0.99
(–0.16 to 2.27)
Biochemical profiles
  sCr (mg/dL) 0.80
(0.58–0.90)
0.59
(0.49–0.64)
0.80
(0.52–1.10)
0.62
(0.55–0.76)
0.63
(0.60–0.65)
0.71
(0.66–0.76)
0.85
(0.65–0.90)
0.75
(0.61–0.81)
  eGFR (mL/
    min/1.73 m2)
110.3
(99.3–151.9)
152.1
(131.8–180.4)
115.8
(77.5–158.7)
136.2
(110.0–157.5)
132.9
(128.2–137.5)
117.7
(108.6–126.8)
131.3
(109.9–181.5)
145.2
(131.1–148.6)
  Urine 
    microalbumin/
    creatinine
    (mg/g)
63.48
(40.18–117.46)
68.59
(42.04–72.26)
56.00
(34.29–241.43)
15.29
(13.23–20.02)
6.21
(3.55–8.88)
38.76
(30.20–47.32)
13.16
(9.29–21.32)
5.96
(3.83–9.13)
  Cholesterol 
    (mg/dL)
218.0
(194–253)
209.0
(147–338)
196.0
(161–231)
174.0
(160–188)
NA NA 162.0
(136–165)
139.0
(136–141)
  TG (mg/dL) 295.0
(179–581)b)
326.0
(320–572)c)
87.0
(85–251)
95.0
(60–149)
181.0
(127–235)
215.0
(168–262)
68.5
(55–106)
64.0
(60–82)
  HDL-cholesterol 
    (mg/dL)
52.0
(51–52)
54.0
(45–57)
64.0
(41–73)
59.0
(44–64)
39.5
(35–44)
43.5
(41–46)
47.5
(43–50)
53.0
(45–66)
  HbA1c (%) 11.2
(7.0–12.2)
11.1
(8.2–12.3)
13.3
(7.6–15.0)
6.3
(6.1–12.1)
6.7
(6.1–7.3)
7.8
(6.4–9.2)
8.3
(5.6–11.1)
6.6
(5.4–11.7)
  C-peptide
    (ng/mL)
3.73
(2.710–3.750)
2.25
(1.960–3.100)
2.08
(1.010–2.230)
2.43
(1.420–3.440)
3.41
(2.470–4.340)
1.83
(1.270–2.390)
3.00
(2.970–3.200)
1.63
(1.180–2.130)
Values are presented as median (interquartile range or range) or number.
T2DM, type 2 diabetes mellitus; BMI, body mass index; sCr, serum creatinine; eGFR, estimated glomerular filtration rate; TG, triglyceride; 
HDL-cholesterol, high density lipoprotein cholesterol; HbA1c, glycosylated hemoglobin; C-peptide, connecting peptide; NA, not available. 
a)P=0.014 for persistent vs. regression, progression groups. b)P=0.040 for persistent, regression, progression and normoalbuminuria groups. 
c)P=0.012 for persistent, regression, progression and normoalbuminuria groups. 
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Results
One hundred and nine patients were T1DM (39 males 
and 70 females) and 18 patients were T2DM (4 males and 14 
females). The median duration of diabetes was 10.1 years and 
5.0 years, respectively (Table 1). Both T1DM and T2DM groups 
had shown the changes of anthropometric indexes between 
baseline and follow-up tests. In T2DM, BMI z-score had shown 
decreasing tendency, but there was no statistical significance. The 
median spot urine microalbumin/creatinine ratios at baseline 
and follow-up were 9.4 mg/g (IQR, 6.3–26.6 mg/g) and 13.3 mg/
g (IQR, 8.6–24.8 mg/g) in T1DM, and 25.3 mg/g (IQR, 11.5–56.0 
mg/g) and 17.7 mg/g (IQR, 6.2–42.0 mg/g) in T2DM, but there 
were no statistical significance. The other profiles include HbA1c 
shown no statistical significance.
The prevalence of microalbuminuria at baseline and follow 
up were 21.1% and 17.4% in T1DM, and 44.4% and 38.9% 
in T2DM (Fig. 1). Patients were divided into 4 groups based 
on results of  repeated microalbuminuria measurements; 
persistent, regression, progression of microalbuminuria and 
normoalbuminuria groups. In 109 T1DM patients, 23 patients 
had microalbuminuria at baseline, of them 13 (56.5%) had 
regression of microalbuminuria, 10 (43.5%) had persistent 
microalbuminuria, and 86 patients had no microalbuminuria 
at  baseline, of  them 9 (10.5%) showed progression of 
microalbuminuria during follow-up period. In 18 T2DM 
patients, 3 (37.5%) had regression of microalbuminuria, 5 (62.5%) 
had persistent microalbuminuria, and 2 (20.0%) had progression 
of  microalbuminuria. Seventy-seven patients (89.5%) in 
T1DM and 8 patients (80.0%) in T2DM had negative results of 
microalbuminuria during follow-up. 
Clinical characteristics and laboratory parameters of 
T1DM and T2DM patients were compared among persistent, 
regression, progression, and normoalbuminuria groups (Tables 
2,3). The duration of diabetes was not different among 4 groups 
in T1DM (P=0.353 at baseline, P=0.455 at follow-up). In T2DM, 
no difference of duration of diabetes was also observed among 
4 groups at baseline (P=0.861), and at follow-up (P=0.366). In 
T1DM, follow-up duration of microalbuminuria was longer 
in regression group compared to persistent (P<0.001) or 
progression groups (P=0.027). HbA1C at baseline (P=0.009) 
and follow-up (P=0.030) was lower in regression group 
compared to persistent or progression groups. C-peptide at 
baseline was higher in regression group compared to persistent 
group (P=0.021). In T2DM, there was no significant difference 
between each group in anthropometric indexes except baseline 
height z-score (P=0.014). And higher triglyceride (TG) was 
observed at both baseline (P=0.040) and follow up (P=0.012) 
in persistent group. Follow-up duration of microalbuminuria 
was not different significantly among T2DM groups (P=0.297). 
Comparison of spot urine microalbumin/creatinine ratio 
between baseline and follow up was presented in Fig. 2.
Discussion
The prevalence of microalbuminuria at baseline and follow-
up were 21.1% and 17.4% in T1DM, and 44.4% and 38.9% in 
T2DM. The regression of microalbuminuria was observed in 
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56.5% of T1DM patients and 37.5% of T2DM patients during 
follow-up. Lower baseline HbA1c (persistent vs. regression, 
P=0.026; progression vs. regression, P=0.057), higher C-peptide 
at baseline (persistent vs. regression, P=0.021) was observed 
in T1DM regression group compared to those in persistent 
or progression groups. In T2DM, patients in persistent group 
had higher TG compared to patients in other groups (baseline, 
P=0.040; follow-up, P=0.012). 
While microalbuminuria was considered as a predictor 
of diabetic nephropathy in both adults and children2,3,16), 
there have been studies which described regression of 
microalbuminuria in diabetic patients6,7,10,12,17-19). Perkins et 
al.10) found frequent regression of microalbuminuria, with 
58% (95% confidence interval, 52–64) incidence at the 6-year 
follow-up in T1DM adult patients. Low HbA1c, low blood 
pressure and low levels of lipid profiles were identified as 
modifiable factors. In the European multicenter study, 50.6% 
of T1DM patients showed regression of microalbuminuria, 
whereas 13.9% showed progression over 7.3 years20). In the 
Oxford regional prospective study, the cumulative prevalence of 
microalbuminuria was 25.7% and 50.7% after 10 and 19 years 
of diabetes, of them 39% regressed to normoalbuminuria, while 
13.9% progressed to macroalbuminuria6). Modifiable predictors 
of macroalbuminuria were high HbA1c, and persistent and 
intermittent microalbuminuria. It was also reported that 72% 
of T1DM children had regression to normoalbuminuria using 
repeated spot urine tests in a single center study12). 
In patients with T2DM, microalbuminuria might be an 
early marker of T2DM, and it could precede a diagnosis of 
T2DM21,22). Therefore, it was recommended for patients with 
T2DM to be screened for microalbuminuria at the beginning 
of diagnosis because the course of renal dysfunction is more 
heterogeneous, and the progression of nephropathy is less 
well characterized compared to that of T1DM17,23). Moreover, 
the effect of  medical treatment on diabetic nephropathy 
in T2DM has not  been ful ly  investigated. Unti l  now, 
microalbuminuria in T2DM patients has been considered 
the first step toward overt proteinuria and nephropathy17). 
However, recent studies reported that microalbuminuria 
in T2DM could be improved to normoalbuminuria17,24). 
Araki et al.24) found frequent remission and/or regression, 
with about 50% incidence at the 6-year follow-up in T2DM 
adult patients. Short duration of  microalbuminuria, the 
use of  renin-angiotensin system blocking drugs, low 
HbA1c and low systolic blood pressure were identified as 
determinants. Gaede et al.25) have reported that 30.5% of 
T2DM patients with microalbuminuria achieved remission 
to normoalbuminuria during 3–8 years, and antihypertensive 
therapy and low HbA1c were independent predictors for 
remission. In Japanese pediatric study, they presented that 
only 20% of children progressed to overt proteinuria, whereas 
40% of children improved to normoalbuminuria among 130 
T2DM patients with microalbuminuria during the follow-
up years (mean±stdndard deviation, 3.4±1.3 years; range, 
2–6 years)17). Female sex, high HDL cholesterol and low 
HbA1c were independently associated with remission and/
or regression of microalbuminuria. In this study, we identified 
frequent regression of microalbuminuria in 56.5% of T1DM 
and 37.5% of T2DM patients with a short follow-up period, 
which is consistent with previous studies6,10-12,17,24). Duration of 
microalbuminuria, HbA1c, blood pressure, lipid concentration 
and use of renin-angiotensin system blocking agents were well 
known risk factors of microalbuminuria26). We found lower 
HbA1c and higher C-peptide at baseline in regression group 
of T1DM, and higher TG in T2DM persistent group. It means 
that adequate control of glucose and lipid concentrations is 
important in diabetic children and adolescents, consistent with 
previous studies6,10,13,18,27-29). Duration of microalbuminuria 
follow-up was longer in T1DM regression group compared to 
persistent or progression groups, while duration of diabetes 
did not differ among subgroups. It suggests the importance of 
frequent monitoring for microalbuminuria in diabetic children 
and adolescents. Early detection of microalbuminuria may lead 
to adequate intervention and, as a result, prevent progression 
toward diabetic nephropathy.
Our study has limitations. First, retrospective nature of study 
design is a limitation. Second, although important clinical and 
laboratory determinants of microalbuminuria were measured 
in the present study, other affecting factors such as blood 
pressure, sodium intake, and the use of angiotensin converting 
enzyme inhibitors or angiotensin receptor blocker were not 
included as a variable. Third, small sample size and short follow-
up period is another limitation. During annual or biannual 
screening of microalbuminuria according to clinical practice 
guideline, frequent regression of microalbuminuria in both 
T1DM and T2DM patients was observed9). Further studies 
including large number of childhood onset diabetes patients 
with long term follow-up period should be followed to identify 
contributing factors and mechanism of progression to overt 
proteinuria. Elevated microalbumin excretion is known to be an 
early marker of progression to diabetic nephropathy, however 
regression of microalbuminuria was observed in substantial 
number of patient. It indicates elevated urinary microalbumin 
excretion in a single test does not imply irreversible diabetic 
nephropathy. Close monitoring and intensive control should be 
emphasized in children and adolescents with microalbuminuria 
to prevent or delay the progression of diabetic nephropathy.
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